Shreehas Tambe assumes charge as MD -; CEO of Biocon Biologics

6 Dec 2022 , 12:09 PM

Shreehas Tambe, Deputy CEO of Biocon Biologics, has been appointed as the Managing Director and CEO, effective December 5, 2022, of Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited.

Tambe will guide BBL toward its goal of becoming a global biosimilar leader.

Tambe succeeds Arun Chandavarkar, who will continue to serve on the Board of Biocon Biologics as a non-executive, non-independent director.

Shreehas Tambe, Deputy CEO of Biocon Biologics since March 2021, has played an important and very effective role in assisting Arun Chandavarkar in steering the company toward sustainable growth and laying a strong foundation for the future.

Shreehas Tambe has been associated with Biocon since 1997, serving in a variety of leadership and operational roles. He has helped build and shape Biocon's biosimilars business over the last 25 years, as well as spearheading the Group's strategic capital investments, including its first overseas facility in Malaysia.

Shreehas has also been instrumental in obtaining regulatory approvals and successfully launching several of the company's biosimilar assets in global markets such as the United States and the European Union.

At around 10.47 AM, Biocon was trading at Rs276.55 down by 0.9% from its previous closing of Rs279.05 on the BSE. The scrip opened at Rs279.95 and touched intraday high and low of Rs280.30 and Rs276.20 respectively.

For feedback and suggestions, write to us at [e-mail]